Product Development Pipeline

Torque is developing a new class of Deep-Primed™ T cell therapeutics for the treatment of cancer. Our immuno-oncology strategy is to:

1. prime and activate T cells to target multiple tumor antigens, and
2. tether immune-stimulatory drugs directly to the surface of these multi-target T cells to stimulate and direct the immune response locally in the tumor microenvironment.

In hematologic cancers, our new class of immune therapeutics has the potential to improve on the initial success of single-target CAR-T therapeutics with expanded efficacy, and also move cell therapy treatment out of the hospital with a high margin of safety. For solid tumors, Deep-Primed T cells have the potential to enable efficacy against tumors with heterogeneous antigens protected by hostile microenvironments, which are not readily addressable with the first generation of immune cell therapies.

We believe there is a significant opportunity to dramatically expand cancer cures, particularly for solid tumors, using Deep-Primed T cells with high cell doses, administered with repeat doses to drive deep and persistent clinical responses.


Torque Product Development Pipeline

Product Candidate


Lead Optimization


Phase 1
Deep IL-15 Primed T Cells
Solid & hematologic tumors
Deep IL-12 Primed T Cells
Solid tumors
Deep TLR Primed T Cells
Solid tumors
Deep Checkpoint Inhibitors
Solid & hematologic tumors

Our initial clinical candidate—Deep IL-15 Primed T Cells—will initiate the first clinical trial in 2018 for both hematologic and solid tumors. In this study, the Deep-Primed T cells will be administered in an outpatient setting without any pre-conditioning regimen, and patients will receive repeat doses of cells, in contrast to current cellular therapy treatment regimens that are limited to single-dose treatment and require both myeloablative preconditioning chemotherapy and hospitalization to monitor and manage toxicities.

We are also developing Deep IL-12 Primed T Cells and small-molecule Deep TLR Primed T Cells to target both adaptive and innate immunity, to amplify the immune response for durability and memory. In addition, we are pursuing several approaches to develop Deep Checkpoint Inhibitors.


Back to Top